Om

LongBio Pharma (Suzhou) Co., Ltd. is a clinical-stage biopharmaceutical company based in Shanghai and Changshu, Suzhou, China. The company focuses on the in-house discovery and development of biologic therapies targeting allergic and autoimmune diseases. Its research and development efforts are centered on antibody-based and bi-functional biologic drugs designed to modulate immune pathways with high specificity. LongBio Pharma’s pipeline addresses multiple therapeutic areas, including rhinology, dermatology, respiratory, hematology, nephrology, and other immune-mediated conditions. Key investigational assets include an anti-IgE antibody and bi-functional complement inhibitors aimed at conditions such as allergic rhinitis, chronic spontaneous urticaria, allergic asthma, and complement-driven renal and hematologic disorders. Operating within the pharmaceuticals and biotechnology sector, LongBio Pharma serves healthcare providers and patients by advancing novel biologic treatment options intended for use in both specialty and hospital settings. Founded in 2020, the company plays an active role in China’s innovative biologics ecosystem, leveraging proprietary technology platforms and internal R&D capabilities to build a diversified clinical pipeline.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I LONGBIO PHARMA SUZHOU CO MED ENDAVU: Køb LongBio Pharma Suzhou Co ($1779) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i LongBio Pharma Suzhou Co, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.